AbCellera Biologics Inc Forecast, price target & analysts
Why the stock moved Beta
AbCellera Biologics Inc Target price 2026 - Analyst rating & recommendation
AbCellera Biologics Inc Classifications & Recommendation
AbCellera Biologics Inc Price Target
| Target Price | $15.30 |
| Price | $13.91 |
| Potential |
9.99%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target AbCellera Biologics Inc 2027 .
The average AbCellera Biologics Inc target price is $15.30.
This is
9.99%
register free of charge
$31.50
126.46%
register free of charge
$9.09
34.65%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend AbCellera Biologics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbCellera Biologics Inc stock has an average upside potential 2027 of
9.99%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 75.13 | 25.86 |
| 160.60% | 65.58% | |
| EBITDA Margin | -259.46% | -793.32% |
| 66.59% | 205.76% | |
| Net Margin | -194.88% | -793.41% |
| 65.50% | 307.14% |
11 Analysts have issued a sales forecast AbCellera Biologics Inc 2026 . The average AbCellera Biologics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an AbCellera Biologics Inc EBITDA forecast 2026. The average AbCellera Biologics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 AbCellera Biologics Inc Analysts have issued a net profit forecast 2026. The average AbCellera Biologics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.49 | -0.67 |
| 10.91% | 36.73% | |
| P/E | negative | |
| EV/Sales | 153.44 |
11 Analysts have issued a AbCellera Biologics Inc forecast for earnings per share. The average AbCellera Biologics Inc EPS is
This results in the following potential growth metrics and future valuations:
AbCellera Biologics Inc...
Current AbCellera Biologics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 29 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 24 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Benchmark |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 29 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 24 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Benchmark:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 05 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
